Two Sigma Securities’s Neuphoria Therapeutics NEUP Stock Holding History

Two Sigma Securities’s Portfolio NEUP Stock Details NEUP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,170	Closed	-$20K	–	3786
2024 Q2	$20K	Buy	+2,170	New	+$23.6K	﹤0.01%	2699

Other funds holding NEUP

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Two Sigma Securities's NEUP Position: Q3 2024 in Review

Two Sigma Securities sold out of Neuphoria Therapeutics (NEUP) in Q3 2024, closing a stake of 2,170 shares — an estimated $20K sold.

Two Sigma Securities first reported a position in NEUP in Q2 2024 and held it in 1 quarter. The position peaked at $20K in Q2 2024. 8 funds tracked by Wall St. Rank hold NEUP as of Q3 2024.

Two Sigma Securities reported no remaining Neuphoria Therapeutics position as of Q3 2024 after selling out during the quarter.
Two Sigma Securities sold 2,170 Neuphoria Therapeutics shares in Q3 2024, an estimated $20K.
Two Sigma Securities first reported a position in Neuphoria Therapeutics in Q2 2024 and held it in 1 quarter.
Two Sigma Securities's Neuphoria Therapeutics position peaked at $20K in Q2 2024.
8 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q3 2024.

Based on Two Sigma Securities's 13F filing for Q3 2024, filed 14 Nov 2024.